Hackensack Meridian Mountainside Medical Center has been approved to use Pluvicto™, an FDA-approved, targeted radioligand therapy for treatment of metastatic prostate-specific membrane antigen positive castration-resistant prostate cancer (PSMA+ mCRPC). Pluvicto™ is the first, and only targeted radioligand therapy for patients with PSMA+ mCRPC. The approval makes Mountainside Medical Center the first in the state to offer treatment using Pluvicto™.

Pluvicto™ emits radioactive agents that target PSMA+ cancer cells in the body, limiting damage to other cells and improve outcomes for patients. This innovation is life-changing for our patients and their loved ones.

Studies show that patients treated with Pluvicto™, after treatment with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy, had a 38% reduction in risk of death compared to AR pathway inhibition and chemotherapy alone. According to the American Cancer Society, prostate cancer is the most common cancer in American men, with an estimated 268,490 new cases and 34,500 deaths projected for 2022.

For more information about Pluvicto, to schedule an appointment or consult a radiation oncologist 973-429-6096 or complete the information below.